RARA CRAFT DATABASE for FDA Medical Devices

FDA Device Decisions, January 2025: Kidney Function Measured Through the Skin, a Muscle-Fatigue Device for Athletes and Two Original PMAs

日本語版

One of FDA's two original PMA approvals in January 2025 went to the MediBeacon Transdermal GFR Measurement System (P230019), which measures glomerular filtration rate with a sensor on the skin. A fluorescent tracer (Lumitrace) is injected into a vein, and the system follows its clearance from the body by light through the skin to calculate GFR.

The month's only De Novo grant was not for diagnosing or treating disease. It went to a device that measures thigh muscle fatigue in healthy athletes 15 and older to inform training decisions.

Counting records held in RA Craft Database (decisions through August 31, 2026, tallied October 6), FDA cleared 253 510(k)s in January 2025, granted 1 De Novo request and approved 2 original PMAs. These counts have not been reconciled with FDA's own figures. The site holds 510(k), De Novo and PMA records from 2015 onward, and counts for past months can change as the data are updated.

Counts by pathway

January 2025 next to the previous month and the same month a year earlier, with records assigned to a month by FDA decision date.

PathwayJanuary 2025December 2024January 2024
510(k)253289209
De Novo126
PMA (original)233
PMA supplement148238140

Records held in RA Craft Database, decisions through August 31, 2026.

510(k) clearances were 36 fewer than in December 2024 but above January 2024 (209). There was 1 De Novo grant and 2 original PMAs.

The busiest product codes

January's 510(k)s spread across 163 product codes. GEI (electrosurgical, cutting & coagulation & accessories) and LLZ (system, image processing, radiological) led with 6 each, followed by DXN (system, measurement, blood-pressure, non-invasive), INI (vehicle, motorized 3-wheeled), JAK (system, x-ray, tomography, computed), MBI (fastener, fixation, nondegradable, soft tissue) and NHA (abutment, implant, dental, endosseous) with 5 each. A single 510(k) can carry more than one product code, so per-code counts can add up to more than the number of submissions. If your code is on the list, enter it in the Product Code field on Search to see the records sorted by decision date.

De Novo: one classification

January's De Novo grant, with the classification name and regulation number from the Classification Order:

  • Myocene (DEN230051, Myocene): Neuromuscular stimulator and evaluation system (21 CFR 882.1871), Class II, product code SDX

"21 CFR" refers to Title 21 of the Code of Federal Regulations, where FDA's regulations are codified.

The classification covers devices that stimulate muscle electrically and measure the response to evaluate exercise capacity and performance or to inform athletic training decisions. Later devices of this type will go through 510(k).

Original PMAs: two approvals

  • ManaFuse (P210016, ManaMed): a home-use bone growth stimulator that uses low-intensity pulsed ultrasound (LIPUS) (product code LOF)
  • MediBeacon Transdermal GFR Measurement System (P230019, MediBeacon Inc.): measures GFR through the skin by tracking the fluorescence of an injected tracer (SDK)

January also brought 148 PMA supplements, which cover changes to already approved PMA devices among other things.

Three devices worth a closer read

1. MediBeacon Transdermal GFR Measurement System (P230019, PMA). Three parts: the injected tracer, a single-use skin sensor and a monitor that calculates GFR. It is for adults with normal or impaired kidney function, but according to the Summary of Safety and Effectiveness Data (SSED) that FDA published with the approval, it is not for patients with GFR below 15 or above 120, patients on dialysis or patients whose kidney function is changing rapidly. In the multicenter pivotal study, 94.0% of results fell within 30% of plasma-measured GFR. As a condition of approval, FDA requires provider and patient fact sheets, which must state that the tracer may interfere with other diagnostic testing for up to 72 hours after injection.

2. Myocene (DEN230051, De Novo). The device stimulates the knee extensors (the quadriceps) and compares the force of voluntary and stimulated contractions to produce measures of muscle fatigue. The users are coaches and athletes, and the population is healthy athletes 15 and older. No disease is involved, yet it is a prescription device. Its six special controls cover non-clinical testing of stimulation output and sensor accuracy, electrical safety, software, biocompatibility, usability and labeling.

3. ManaFuse (P210016, PMA). A handheld ultrasound device applied over the fracture site for 20 minutes a day. It is indicated for established non-unions and for accelerating healing of certain distal radius and tibial shaft fractures managed by closed reduction and casting. There was no ManaFuse clinical trial. According to the SSED, FDA applied the six-year rule (FDAMA Section 216), which allows use of clinical data from a PMA approved more than six years earlier, and accepted reliance on the clinical data for EXOGEN (P900009) after bench testing showed equivalent signal output.

Compare the three devices

Open P230019, DEN230051 and P210016, star (☆) each one, tick "Compare" on all three in My Workspace and press "3 selected for comparison". The comparison table puts their Indications for Use side by side. Before relying on any of this, open "FDA Record" and "Summary PDF" on each record and read the source.

Note: months are assigned by FDA decision date, and counts can change as the data are updated each month.

RA Craft Database is an independent service and is not affiliated with or endorsed by the U.S. FDA. Articles are for general information on product development and regulatory research; they are not legal or regulatory advice for a specific device. Official FDA documents remain the authoritative source.

← All articles